Cell Signaling Technology

Product Pathways - NF-kB Signaling

RANK Ligand (L300) Antibody #4816

Applications Reactivity Sensitivity MW (kDa) Source
W IP H M (R) (Mk) (Pg) (B) Endogenous 35-45 Rabbit

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  M=Mouse  R=Rat  Mk=Monkey  Pg=Pig  B=Bovine
Species cross-reactivity is determined by Western blot.

Protocols

Specificity / Sensitivity

RANK Ligand (L300) Antibody detects endogenous levels of RANK Ligand. The antibody is predicted to detect soluble RANK Ligand.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxyl terminus of human RANK Ligand. Antibody was purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from COS-7 cells, untransfected (-) or transfected with a construct expressing RANK Ligand, using RANK Ligand (L300) Antibody.

Western Blotting

Western Blotting

Western blot analysis of extracts from various cell lines using RANK Ligand (L300) Antibody.

Background

RANK (receptor activator of NF-κB) is a member of the tumor necrosis factor (TNF) receptor subfamily that is activated by its ligand, RANKL (TRANCE/OPGL/ODF), to promote survival of dendritic cells and differentiation of osteoclasts (1-4). Although RANK is widely expressed, its cell surface expression may be more restricted to dendritic cells and foreskin fibroblasts (1). RANK contains a 383-amino acid intracellular domain that associates with specific members of the TRAF family to NF-κB and JNK activiation (1,5). RANKL/RANK signaling may also lead to survival signaling through activation of the Akt pathway and an upregulation of survival proteins, including Bcl-xL (2,6). RANK signaling has been implicated as a potential therapeutic to inhibit bone loss and arthritis (7,8).

RANKL (1), also named TNF-related activation-induced cytokine (TRANCE) (2,9), osteoprotegerin ligand (OPGL) (3), osteoclast differentiation factor (ODF) (4), and TNFSF11, is a type II transmembrane protein of the TNF family that exists as both a membrane-bound and soluble form. It is an essential regulator of immune function and bone development and homeostasis (7,10,11). RANKL is predominately expressed in activated T cells, as well as the thymus, lymph node, and bone marrow and promotes dendritic cell survival. Deletion of RANKL in mice leads to severe osteoporosis with a loss of osteoclasts, defects in T and B cell differentiation, loss of lymph node development, and mammary gland development during pregnancy (12-14).

  1. Anderson, D.M. et al. (1997) Nature 390, 175-9.
  2. Wong, B.R. et al. (1997) J. Exp. Med. 186, 2075-80.
  3. Lacey, D.L. et al. (1998) Cell 93, 165-76.
  4. Yasuda, H. et al. (1998) Proc. Natl. Acad. Sci. USA 95, 3597-602.
  5. Darnay, B.G. et al. (1998) J. Biol. Chem. 273, 20551-5.
  6. Wong, B.R. et al. (1999) Mol. Cell 4, 1041-9.
  7. Walsh, M.C. and Choi, Y. Cytokine Growth Factor Rev. 14, 251-63.
  8. Nakashima, T. et al. (2003) Curr. Opin. Rheumatol. 15, 280-7.
  9. Wong, B.R. et al. (1997) J Biol Chem 272, 25190-4.
  10. Hofbauer, L.C. (1999) Eur J Endocrinol 141, 195-210.
  11. Theill, L.E. et al. (2002) Annu Rev Immunol 20, 795-823.
  12. Mizuno, A. et al. (1998) Biochem Biophys Res Commun 247, 610-5.
  13. Kong, Y.Y. et al. (1999) Nature 397, 315-23.
  14. Fata, J.E. et al. (2000) Cell 103, 41-50.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

Products